BBA
OVID icon

Baader Bank Aktiengesellschaft’s Ovid Therapeutics OVID Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,282
Closed -$8.32K – 518
2024
Q2 		$8.32K Buy
+13,282
New +$37K ﹤0.01% 394

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Baader Bank Aktiengesellschaft's OVID Position: Q3 2024 in Review

Baader Bank Aktiengesellschaft sold out of Ovid Therapeutics (OVID) in Q3 2024, closing a stake of 13,282 shares — an estimated $8.32K sold.

Baader Bank Aktiengesellschaft first reported a position in OVID in Q2 2024 and held it in 1 quarter. The position peaked at $8.32K in Q2 2024. 75 funds tracked by Wall St. Rank hold OVID as of Q3 2024.

  • Baader Bank Aktiengesellschaft reported no remaining Ovid Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 13,282 Ovid Therapeutics shares in Q3 2024, an estimated $8.32K.
  • Baader Bank Aktiengesellschaft first reported a position in Ovid Therapeutics in Q2 2024 and held it in 1 quarter.
  • Baader Bank Aktiengesellschaft's Ovid Therapeutics position peaked at $8.32K in Q2 2024.
  • 75 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2024.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q3 2024, filed 29 Oct 2024.